Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 188

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 188
---
 used in assessing the performance of the reportable segments and to allocate resources across our reportable segments. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with GAAP.

113

A reconciliation of sales and operating income for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.Year Ended December 31, 2024MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$5,973 $10,711 $16,683 Impact of foreign currency fluctuations64 Total net sales16,747 Segment expenses:Cost of products sold1,649 27.6 %3,404 31.8 %5,053 Selling, general and administrative expenses1,801 30.2 %3,166 29.6 %4,967 Research and development expenses462 7.7 %975 9.1 %1,437 Other segment items(1)14 0.2 %19 0.2 %33 Segment operating income(2)2,046 34.3 %3,147 29.4 %5,193 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(663)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(1,070)Amortization expense(856)Operating income (loss) 2,603 Other income (expense), net(321)Income (loss) before income taxes$2,282 

114

Year Ended December 31, 2023MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$5,378 $8,714 $14,091 Impact of foreign currency fluctuations149 Total net sales14,240 Segment expenses:Cost of products sold1,470 27.3 %2,805 32.2 %4,276 Selling, general and administrative expenses1,626 30.2 %2,749 31.5 %4